Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy.

Echocardiography for Evaluation of Oncology Therapy-Related Cardiotoxicity. Acta Cardiol Sin (2016) 0.75

Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy. Int J Cardiovasc Imaging (2017) 0.75

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32

Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr (2009) 14.63

Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet (2010) 11.06

Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med (2000) 6.27

Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 6.09

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol (2010) 5.99

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol (2005) 4.77

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 4.57

Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation (2008) 3.25

Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr (2011) 2.97

Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol (2014) 2.95

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol (2010) 2.18

Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol (2012) 2.18

Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr (2012) 2.17

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr (2014) 1.88

Prognostic significance and normal values of 2D strain to assess right ventricular systolic function in chronic heart failure. Circ J (2011) 1.60

Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol (2013) 1.48

Role of right ventricular systolic function on long-term outcome in patients with newly diagnosed systolic heart failure. Circ J (2011) 1.46

Range of normal values for left and right ventricular ejection fraction at rest and during exercise assessed by radionuclide angiocardiography. Eur Heart J (1985) 1.33

Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr (2007) 1.28

Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol (2010) 1.11

CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging (2014) 1.04

Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol (1983) 1.00

Assessment of right ventricular functions during cancer chemotherapy. Eur J Echocardiogr (2011) 0.97

Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol (2013) 0.96

Right ventricular strain in pulmonary arterial hypertension: a 2D echocardiography and cardiac magnetic resonance study. Echocardiography (2014) 0.89

Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women. Eur J Nucl Med (1996) 0.88

The evaluation of doxorubicin-induced cardiotoxicity: comparison of Doppler and tissue Doppler-derived myocardial performance index. Cardiol J (2012) 0.86

Incidence, predictors, and impact on survival of left ventricular systolic dysfunction and recovery in advanced cancer patients. Am J Cardiol (2014) 0.85

Right ventricle wall motion abnormalities in patients treated with chemotherapy. Clin Nucl Med (1991) 0.82

Tissue Doppler and myocardial deformation imaging to detect myocardial dysfunction in pediatric cancer patients treated with high doses of anthracyclines. Asia Pac J Clin Oncol (2012) 0.81